08.11.2024  17:35:35 Изменение +7.20 Объем сделки Бид08.11.2024 Предложение08.11.2024 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
305.20EUR +2.42% 129
Оборот: 38,675.30
-Величина цены спроса: - -Величина цены предложения: - 163.14 млрдEUR - -

Описание деятельности

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
 

Правление & Наблюдательный совет

Исполнительный директор
Robert Bradway
Правление
Peter H. Griffith, Annalisa Pizzarello, Anton Rabushka, Arleen Paulino, Darryl Sleep, David A. Piacquad, David M. Reese, Esteban Santos, Gilles Marrache, Ian Thompson, Jean-Charles Soria, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mark J. Taisey, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Rachna Khosla, Raymond Deshaies, Rob Lenz, Susan Sweeney, Victoria H. Blatter
Наблюдательный совет
Robert A. Bradway, Amy E. Miles, Brian J. Druker, Charles M. Holley Jr., Ellen J. Kullman, Greg C. Garland, Michael V. Drake, R. Sanders Williams, Robert A. Eckert, Ronald D. Sugar, S. Omar Ishrak, Tyler Jacks, Wanda M. Austin
 

Данные компании

Имя: Amgen Inc.
Адрес: One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA
Телефон: +1-805-447-1000
Факс: +1-805-447-1010
E-mail: investor.relations@amgen.com
Интернет: www.amgen.com
Индустрия: Healthcare
Сектор: Medical Products
Подсектор: Advanced Medical Devices
Конец финансового года: 31.12
Акции в свободном обращении: 76.20%
Дата IPO: 17.06.1983

Связи с инвесторами

Имя: -
IR телефон: +1-805-447-1060
IR-факс: -
IR e-mail: investor.relations@amgen.com

Основные акционеры

Другие
 
71.83%
Vanguard Group Inc
 
9.15%
State Street Corp
 
5.50%
Primecap Management Co/Ca/
 
2.72%
Morgan Stanley
 
2.69%
Geode Capital Management, Llc
 
2.30%
Charles Schwab Investment Management Inc
 
1.94%
Wells Fargo & Company/Mn
 
1.40%
Capital Research Global Investors
 
1.25%
Другие
 
1.22%